Biofrontera (B8F) Q1 2026 Earnings Report

The call presented meaningful operational and clinical progress: double-digit revenue growth (17% YoY), a substantial gross margin expansion to ~80% following the strategic transaction, near-breakeven operating cash usage ($70k), strong clinical/regulatory milestones (sNDA accepted with PDUFA date, positive Phase III AK data, encouraging acne Phase II), and regained NASDAQ compliance. Offsetting these positives are persistent GAAP losses (net loss $4.8M), higher SG&A (up ~27%), patent/legal and manufacturing transition costs, modest cash reserves ($6.3M) with a going concern qualification, and exposure to tariff/supply risks. Overall, the highlights—particularly the margin improvement, cash-flow progress, and clinical/regulatory advances—meaningfully outweigh the lowlights, though execution and financing risks remain.

Management guided a 2026 path to cash‑flow breakeven supported by Q1 results: product revenues $10.1M (+17% YoY from $8.6M), Ameluz volumes ~29,000 tubes (+16% from ~25,000), a Q1 price lift that added ~$0.2M, 32 RhodoLED lamps shipped (installed base ~773 lamps in 709 offices), and a gross margin of ~80% (vs ~62% YoY) driven by a ~40% decline in cost of goods ($3.1M to $1.8M) and a $1.2M earnout (earnout terms: 12% of net sales ≤ $65M, 15% > $65M); financials also showed adjusted EBITDA of -$3.6M (margin -35% vs -51%), operating loss $4.3M, net loss $4.8M ($0.41/sh), cash used in operations ~$70k (vs $4.1M), cash $6.3M (vs $6.4M), a $3.4M AR collection, expectation to file an sNDA for AK in Q3, a sBCC PDUFA on Sept 28, 2026, and a long‑term gross margin target of 80–85% (patent protection through 2043).